BioCentury | May 30, 2016
Company News

Nanosphere, Luminex deal

Luminex increased its bid to acquire fellow diagnostic company Nanosphere to $1.70 per share in cash, or about $77 million. Luminex increased its bid from $1.35 per share in cash after Nanosphere received an unsolicited...
BioCentury | Sep 14, 2015
Clinical News

RP Flex regulatory update

FDA granted 510(k) clearance to Nanosphere’s Verigene Respiratory Pathogens Flex Nucleic Acid Test (RP Flex) to identify and detect viruses and bacteria that most commonly cause respiratory infections. The qualitative in vitro nucleic acid test...
BioCentury | Sep 15, 2014
Company News

Nanosphere diagnostic news

Molecular Diagnostics company Nanosphere hired Jefferies as a financial advisor to assist in developing and evaluating strategic alternatives. The company said it does not plan to disclose additional details on the process until further disclosure...
BioCentury | Jul 14, 2014
Company News

Nanosphere Inc, HealthTrust Purchasing Group L.P. sales and marketing update

Nanosphere signed an agreement with group purchasing organization HealthTrust to provide the company’s Verigene multiplex molecular diagnostics for infectious diseases to nearly 1,400 HealthTrust acute care facilities. The tests detect infections of the bloodstream, respiratory...
BioCentury | Oct 7, 2013
Clinical News

Verigene Gram-Positive Blood Culture: Postmarketing study data

Researchers at University of Florida Health Jacksonville reported data from 74 in-patients with enterococcal bacteremia showing that implementation of Nanosphere's Verigene BC-GP test significantly reduced mean hospital length of stay by 21.7 days (43.2 vs....
BioCentury | Oct 1, 2013
Clinical News

Nanosphere's BC-GP test reduces hospital stay, costs

Researchers at University of Florida Health Jacksonville reported data from 74 in-patients with enterococcal bacteremia showing that implementation of the Verigene Gram-Positive Blood Culture (BC-GP) Nucleic Acid test from Nanosphere Inc. (NASDAQ:NSPH) significantly reduced mean...
BioCentury | Sep 13, 2013
Financial News

Nanosphere raises $26.3 million in follow-on

Molecular diagnostics company Nanosphere Inc. (NASDAQ:NSPH) raised $26.3 million through the sale of 15 million shares at $1.75 in a follow-on underwritten by Piper Jaffray; Canaccord; and Cowen. Nanosphere proposed the offering late Thursday, when...
BioCentury | Mar 4, 2013
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/1 cls Affymax Inc. (NASDAQ:AFFY) MLV Ed Arce Downgrade Hold (from buy) -84% $2.68 Stifel Nicolaus Joel Sendek Downgrade Hold (from buy) Arce also...
BioCentury | Dec 17, 2012
Clinical News

Verigene C regulatory update

Nanosphere said FDA granted 510(k) clearance for its Verigene C. difficile Test. The in vitro diagnostic detects the toxin A and B gene sequences of Clostridium difficile and identifies the BI/NAP1/027 hypervirulent strain, which Nanosphere...
BioCentury | Nov 19, 2012
Clinical News

Verigene CYP2C19 Nucleic Acid Test regulatory update

Nanosphere said FDA granted 510(k) clearance for its Verigene CYP2C19 Nucleic Acid Test as an aid for clinicians to determine therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. The in vitro diagnostic,...
Items per page:
1 - 10 of 56
BioCentury | May 30, 2016
Company News

Nanosphere, Luminex deal

Luminex increased its bid to acquire fellow diagnostic company Nanosphere to $1.70 per share in cash, or about $77 million. Luminex increased its bid from $1.35 per share in cash after Nanosphere received an unsolicited...
BioCentury | Sep 14, 2015
Clinical News

RP Flex regulatory update

FDA granted 510(k) clearance to Nanosphere’s Verigene Respiratory Pathogens Flex Nucleic Acid Test (RP Flex) to identify and detect viruses and bacteria that most commonly cause respiratory infections. The qualitative in vitro nucleic acid test...
BioCentury | Sep 15, 2014
Company News

Nanosphere diagnostic news

Molecular Diagnostics company Nanosphere hired Jefferies as a financial advisor to assist in developing and evaluating strategic alternatives. The company said it does not plan to disclose additional details on the process until further disclosure...
BioCentury | Jul 14, 2014
Company News

Nanosphere Inc, HealthTrust Purchasing Group L.P. sales and marketing update

Nanosphere signed an agreement with group purchasing organization HealthTrust to provide the company’s Verigene multiplex molecular diagnostics for infectious diseases to nearly 1,400 HealthTrust acute care facilities. The tests detect infections of the bloodstream, respiratory...
BioCentury | Oct 7, 2013
Clinical News

Verigene Gram-Positive Blood Culture: Postmarketing study data

Researchers at University of Florida Health Jacksonville reported data from 74 in-patients with enterococcal bacteremia showing that implementation of Nanosphere's Verigene BC-GP test significantly reduced mean hospital length of stay by 21.7 days (43.2 vs....
BioCentury | Oct 1, 2013
Clinical News

Nanosphere's BC-GP test reduces hospital stay, costs

Researchers at University of Florida Health Jacksonville reported data from 74 in-patients with enterococcal bacteremia showing that implementation of the Verigene Gram-Positive Blood Culture (BC-GP) Nucleic Acid test from Nanosphere Inc. (NASDAQ:NSPH) significantly reduced mean...
BioCentury | Sep 13, 2013
Financial News

Nanosphere raises $26.3 million in follow-on

Molecular diagnostics company Nanosphere Inc. (NASDAQ:NSPH) raised $26.3 million through the sale of 15 million shares at $1.75 in a follow-on underwritten by Piper Jaffray; Canaccord; and Cowen. Nanosphere proposed the offering late Thursday, when...
BioCentury | Mar 4, 2013
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/1 cls Affymax Inc. (NASDAQ:AFFY) MLV Ed Arce Downgrade Hold (from buy) -84% $2.68 Stifel Nicolaus Joel Sendek Downgrade Hold (from buy) Arce also...
BioCentury | Dec 17, 2012
Clinical News

Verigene C regulatory update

Nanosphere said FDA granted 510(k) clearance for its Verigene C. difficile Test. The in vitro diagnostic detects the toxin A and B gene sequences of Clostridium difficile and identifies the BI/NAP1/027 hypervirulent strain, which Nanosphere...
BioCentury | Nov 19, 2012
Clinical News

Verigene CYP2C19 Nucleic Acid Test regulatory update

Nanosphere said FDA granted 510(k) clearance for its Verigene CYP2C19 Nucleic Acid Test as an aid for clinicians to determine therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. The in vitro diagnostic,...
Items per page:
1 - 10 of 56